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INTRODUCTION 
Recent advances in oncology have focused on 
identifying drugs with improved selectivity for malignant 
cell versus normal cell as means to improve both the 
efficacy and tolerability of cancer treatment. One 
approach for enhancing and improving selectivity is to 
identify therapeutic targets with altered levels of 
expression on malignant versus normal cells and direct 
therapy against those targets. The introduction of 
monoclonal antibody (MAb) technology by Kohler and 
Milstein in 19751 led to thorough efforts to develop 
MAbs as highly selective antitumor therapeutics; 
however the immunogenicity of the very first generation, 
murine MAbs limited their application as therapeutics. 
The ability to obtain fully human MAbs from transgenic 
mice and by phage display has further enhanced and 
elaborated the clinical potential of these approaches 2–4. 
There are currently 9 unconjugated MAbs approved by 
the FDA as cancer therapeutics. These MAbs include 2 
chimeric, 4 humanized and 3 fully human monoclonal 
antibodies that display antitumor activity via blocking 
ligand/receptor interactions, or induce cell killing by 
means of antibody dependent cellular cytotoxicity 
(ADCC), or complement dependent cytotoxicity (CDC) 
5. Monoclonal antibodies have also been used to 
selectively deliver radionuclides 6,7, plant and bacterial 
toxins, 8–10 and a large variety of cytotoxic drugs 11–14. 
MAb directed delivery of cytotoxic drugs is an area of 
intense and keen interest and there are currently at least 
25 antibody drug conjugates (ADCs) undergoing clinical 
evaluation in oncology.  
CHARACTERISTICS OF ANTIBODY DRUG 
CONJUGATES (ADC’S) 
Antibody drug conjugates comprises of a MAb 
chemically coupled to a linker and a cytotoxic drug 
(Figure1). Mechanistically, ADCs are developed to be 
stable in circulation and to effect intracellular drug 
release followed by antigen-specific binding and 
internalization of the ADC. Currently the designing of 
ADCs as therapeutics has been focusing almost 
exclusively on the treatment of cancer. In contrast to 
small molecule cancer agents or function blocking 
MAbs, the targets for ADCs do not need to be causal in 
tumor progression. Rather those target antigens need to 
be most differentially expressed on the cell surface of 
malignant cells relative to normal tissues. The MAbs 
employed in first generation ADCs have identified cell 
surface antigens with different levels of tumor selectivity 
and also included MAbs that internalized following 
antigen binding and those that did not. To be highly 
effective, non-internalizing ADCs needed to remain 
intact into the circulation i.e. not release the hold of drug 
before reaching the target site and yet selectively release 
active drug at the tumor specific site. Typically, these 
ADCs made use of peptidyl linkers which were designed 
to be cleaved by enzymes like cathepsins and matrix 
metalloproteinases expressed dominantly at the tumor 
site, or linkers that would be releasing the  drug by 
hydrolysis at a slightly acidic pH as observed in many 
solid tumors. 
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For most of the  part, these non-internalizing ADCs did 
not show much significant antigen-specific activity and 
did not significantly improve the therapeutic index 
(maximum tolerated dose/active dose) in contrast to that 
of the free drug 15,16. The use of the MAbs that cause 
internalization following antigen binding has led to the 
designing of linkers that are stable in circulation and 
efficiently release the active drug following antigen 
specific binding, internalization and trafficking to 
endosomes/lysosomes 17–19. Internalizing of ADCs has 
demonstrated a highly impressive preclinical 20–23 and 
clinical 24–29 activity.  
 
Figure 1: Schematic illustrating an Antibody Drug 
Conjugate (ADC) 
ADCS: PHARMACOKINETIC ADVANTAGE 
VERSUS CHEMOTHERAPY 
Traditional chemotherapy employs potent small 
molecules to destroy rapidly dividing cells, often through 
antimitotic or DNA-hampering mechanisms. Systemic 
administration of these drugs results in not only tumor 
killing and also damaging the healthy cells. The balance 
between these 2 actions plays a limiting factor in the 
efficacy and tolerability of single-agent chemotherapy. 
As a result, most of the cancer regimens consist of 
combinations of chemotherapeutic agents, each one of 
them administered at or near the maximum tolerated 
dose and for a very limited duration due to their uptake 
and leading to cumulative damage to normal tissues 30. 
The rapid clearance of these small molecules and 
increase in hydrostatic pressure in the solid tumors has 
further decreased the tumor-specific activity of 
chemotherapy. In contrast, monoclonal antibodies, are 
large molecules (150 kDalton) that can be effectively 
retained in the vasculature for  about several weeks and 
slowly diffuse into the  perivascular tissue 31,32.The 
complementarity-determining regions can efficiently 
provide high-affinity binding which is  directed against 
cell-surface antigens on tumor cells. The combination of 
a long half-life, specificity for tumor cells and high 
binding affinity results in the accumulation of antibody 
at the tumor site over a period of time. The lack of direct 
and serious cytotoxicity often facilitates prolonged 
treatment that is well tolerated and relatively safe. 
However, most monoclonal antibodies have very limited 
single-agent activity against cancer cells and are 
frequently used in combination with chemotherapy. 
Despite of a long time of active research and 
development, only 9 naked antibodies directed at 6 
molecular targets have currently been approved by the 
US Food and Drug Administration (US-FDA) for cancer 
therapy (Table 1) 31. ADCs are fabricated to take 
advantage of both the potent cell-killing activities of 
small molecules and the pharmacokinetic and bio-
distribution potential of monoclonal antibodies.19 ADCs 
have empowered antibodies by chemically conjugating a 
cytotoxic payload that can be effectively deliver and 
release that cytotoxic drug at the tumor while limiting 
systemic exposure to the cytotoxic agent. The proposed 
mechanisms of action for an ADC include; antibody 
engagement with a cell-surface target on cancerous cells, 
internalization and intracellular accumulation of the 
intact macromolecule to the lysosomes, rapidly releasing 
of the cytotoxic agent, and finally leading to efficient 
degeneration of tumor cells. 
  
Table 1: Unconjugated monoclonal antibodies approved for cancer 
Target Antibody Therapeutic Indication First US Approval 
CD20 Rituximab NHL 1997 
CD20 Ofatumumab CLL 2009 
Her2 Trastuzumab Breast Cancer 1998 
Her2 Pertuzumab Breast Cancer 2012 
CD52 Alemtuzumab CLL 2001 
EGFR Cetuximab Colon Cancer 2004 
EGFR Panitumumab Colon Cancer 2006 
VEGF Bevacizumab Colon Cancer 2004 
CTLA-4 Ipilimumab Melanoma 2011 
 
There are specifically 5 important elements in the 
designing of effective ADCs: (1) The Molecular Target; 
(2) The Delivery Vehicle (monoclonal antibody or 
alternative scaffold); (3) Chemical Conjugation (method, 
site, and stoichiometry); (4) The Linker, including the 
suitable mechanism of drug release; and (5) The 
Cytotoxic Agent or Payload 34,35. Current concepts for 
each of these elements are explicitly addressed in this 
review. 
MECHANISM OF ACTION 
A successful ADC consists of a MAb - a versatile 
platform for anticancer therapy which is capable of 
binding to the surface of tumour cell-specific antigens 
[35]. These antigens include over-expressed B-cell surface 
proteins in non-Hodgkin’s lymphoma (NHL) such as 
CD19, CD20, CD21, CD22, CD40, CD72, CD79b and 
CD180, extending to the T-cell proteins CD25 and CD30 
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of the immune system. Moreover, proteins that are over 
expressed on carcinoma cells, including the human 
epidermal growth factor receptor 2 (HER2); prostate-
specific membrane antigen (PSMA) and cryptic family 
protein 1 B (Cripto) are also antigens. These tumour-
associated antigens have been studied as potential 
treatments for the following oncology indications: 
leukemia, lymphoma and multiple myeloma 36. The 
function of cytotoxic drugs (e.g. auristatins, 
maytansinoids and calicheamicins), are designed to 
induce tumour cell death, by causing irreversible DNA 
damage and/or interfering with the mechanism of cell 
division 37. The theory behind the mechanism of action 
of ADCs (Figure 2) involves the following processes: 
Binding (Stage 1) - The MAb component of the ADC 
binds to the target antigen on the surface of the tumour 
cell to produce an ADC-antigen (ADC-CDX) complex, 
which is engulfed into a clathrin-coated vesicle; 
Clathrin-Mediated Endocytosis (Stage 2) - This 
binding then initiates a cascade of events, involving the 
internalization of the ADC-antigen clathrin coated 
vesicle into the tumour cell. Consequently, the vesicle 
loses its coat and enables the ADC-antigen complex to 
fuse with an early sorting endosome, to initiate the 
release of the antigen from the ADC. At this stage, the 
antigen may be recycled back to the cell membrane. 
Furthermore, the early endosome converts to a late 
endosome containing the ADC; Degradation (Stage 3) – 
The internalized ADC is transported through the late 
endosome pathway to the intracellular compartment of a 
lysosome, where it is degraded to release the cytotoxic 
drug. The cleavable linkers rely on processes inside the 
cell to liberate the cytotoxic drug such as reduction of 
disulfide bonds mediated by glutathione (GSH) in the 
cytoplasm, exposure to acidic conditions (pH ~4) in the 
lysosome, or cleavage by specific proteases within the 
cell. Conversely, non-cleavable linkers require catabolic 
degradation 38 of the Mab, to release the cytotoxic drug 
retaining the linker and amino acid (lysine) residue, by 
which it was attached to the MAb; Release (Stage 4) – 
The cytotoxic drug enters the cytoplasm, where it binds 
to its molecular target. In route A- calicheamicin based 
drugs 39 interact with the minor groove of DNA and in 
route B -auristatins and maytansinoids disrupt the 
microtubules 40. Subsequently, the cytotoxic drug may 
also pass through the cell membrane and enter other cells 
in close proximity thereby mediating a bystander killing 
effect; Stage 5 – Cell Death: The interaction of the 
cytotoxic drug with DNA and microtubules initiates a 
chain of events leading to apoptosis 41. 
 
 
Figure 2: Schematic representation of the ADC-Antigen internalization process 
VARIOUS AVAILABLE LINKERS AND DRUGS 
To be sufficiently and desirably effective, an ADC must 
selectively bind, internalize and deliver an adequate 
intracellular concentration of drug that is sufficient to 
result in cell death and cancer cell degeneration (Figure 
2). While in general, the conjugation strategies and 
methodologies used in ADC designing should have 
minimal effects on MAb affinity but still there are 
limited data available that can be used to define the 
optimal, or even the minimal, affinity that is required for 
an effective ADC fabrication. Rather than MAb affinity 
being the driver of ADC efficacy it is likely that the 
selectivity, efficiency of internalization and intracellular 
accumulation of a given MAb in composite will define 
an efficacious, potent and safe ADC. The copy number 
and heterogeneity of antigen expression must be 
considered in the selection of drug and linker. This is 
particularly very important for antigens expressed 
heterogeneously within a tumor where ADCs with local 
bystander activity 42,43 may be particularly be essentially 
desirable. The linker should be suitably stable in 
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circulation to facilitate the long circulating half-life of 
the MAb and yet release active drug following antigen-
mediated internalization. Linkers can be broadly 
classified on the basis of their mechanism of drug 
release. Cleavable linkers release drug by hydrolysis or 
enzymatic cleavage following internalization whereas 
non-cleavable linkers, release drug via degradation of the 
MAb into lysosomes following antigen-specific 
internalization 17,44-47. In addition to the mechanism of 
drug release, the specific site of conjugation, the potency 
of the drug and the average number of drug molecules 
per antibody needs to be carefully considered in the 
selection of the linker. Early ADCs incorporated drugs 
such as methotrexate 48-50, vinblastine 51,52 and 
doxorubicin 11,18,53,54 each of which had displayed clinical 
activity as free drugs. In general these ADCs have 
demonstrated antigen-specific activity in vitro and in 
vivo but they required high dose levels of ADC to 
achieve substantial and appreciable antitumor activity. A 
variety of approaches have been evaluated to increase the 
potency of these ADCs including increasing the quantity 
of drug delivered per MAb. In the case of doxorubicin 
conjugates, increasing the drug:MAb ratio over a range 
of 1–25 molecules of drug/MAb was achieved by direct 
conjugation 55, the use of branched linkers 56,57 or 
polymeric carriers 58. 
 
 
 
  
 
Figure 3: Various Linkers used in Antibody Drug Conjugates, (A)- MAb calicheamicin cleavable hydrazone linker; 
(B)- MAb-monomethyl auristatin E cleavable dipeptide (valine citrulline) linker; (C)- MAb-Monomethyl auristatins F 
non-cleavable thioether linker; (D)-MAb Maytansine DM1 non-cleavable thioether linker; (E)- MAb Maytansine DM1 
cleavable disulfide linker; (F)-MAb Maytansine DM4 cleavable disulfide linker. 
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Table 2: Antibody Drug Conjugates in Clinical Development 
 
Candidate 
(Target Antigen) 
Antibody-Drug Conjugate 
[Mab]-[Linker]-[Drug] 
Oncology Indication Developer 
Phase lll of clinical development 
 
Inotuzumab ozogamicin 
(CD22) 
[Hz IgG4]-[Hydrazone]-[Calicheamicin] NHL Pfizer 
Gemtuzumab 
ozogamicin 
(CD33) 
[Hz IgG4]-[Hydrazone]-[Calicheamicin] Relapsed 
AML 
Pfizer 
Phase ll of clinical development 
 
Lorvotuzumab 
mertansine 
(CD56) 
[Hz IgG1] - [SPP] - [Maytansine DM1] Solid Tumours,MM ImmunoGen 
Glembatumumab 
vedotin 
(GPNMB) 
[Hu IgG2] - [Valine-citrulline] - [Auristatin 
MMAE] 
Breast Cancer, 
Melanoma 
Celldex 
Therapeutics 
SAR-3419 
(CD19) 
[Hz IgG1] - [SPDB] - [Maytansine DM4] NHL Sanofi 
PSMA ADC 
(PSMA) 
[Hu IgG1] -[Valine-Citruline]- [Auristatin 
MMAE] 
Prostate Cancer Progenics 
RG7593/DCDT2980S 
(CD22) 
[Hz IgG1] - [Valine-Citruline]- [Auristatin 
MMAE] 
NHL Genentech 
Roche 
RG-7596 
(CD79b) 
[Hz IgG1] -[Valine-Cituline] - [Auristatin 
MMAE] 
NHL Genentech 
Roche 
BT-062 
(CD138) 
[Ch IgG4] - [SPDB] - [Maytansine DM4] MM Biotest 
Phase l of clinical development 
 
SGN-75 
(CD70) 
[Hz IgG1] -[Malemidocaproyl] -[Auristatin 
MMAF] 
NHL,RCC Seattle 
Genetics 
BAY 79-4620 
(CA-IX) 
[Hu IgG1]-[Valine-citruline]-[auristatin 
MMAE] 
Solid Tumours Bayer 
Milatuzumab 
doxorubicin 
(CD74) 
[Hz IgG1] -[Hydrazone]- [Doxorubicin] MM Immunomedics 
AGS-5ME 
(SLC44A4) 
[Hu IgG2] -[Valine-Citruline]-[Ausistatin 
MMAE] 
Pancreatic, Prostate 
Cancer 
Astellas 
BAY 94-9343 
(Mesothelin) 
[Hu IgG1] - [SPDB]-[Maytansine DM4] Solid Tumuors Bayer 
ASG-22ME 
(Nectin-4) 
[Hu IgG1] -[Valine-Citruline] -[Auristatin 
MMAE] 
Solid Tumours Astellas 
Abbreviations-Ch:chimeric;Hz:humanized;hu; fully human;MMAE:monomethyl auristatins E;MMAF:monomethyl 
auristatinF;NHL;non-Hodgkin's Lymphoma;PSMA:Prostate - Specific Membrane Antigen; RCC:Renal Cell Carcinoma; 
GPMNB:Glycoprotein NMB;AML:Acute Myeloid Leukaemia; MM:Multiple Myeloma;CRC:Colorecta Carcinoma. (Source: 
www.clinicaltrials.gov, 2013). 
 
PREPARATION OF ANTIBODY DRUG 
CONJUGATES (ADC’S) 
Figure 4 displays a generic process overview of various 
process steps involved in ADC manufacturing using a 
non-cleavable Succinimidyl-4-(N-maleimidomethyl) 
cyclohexan-1-1carboxylate (SMCC) linker. The 
Succinimidyl-4- (N-maleimidomethyl) cyclohexan-1- 
carboxylate (SMCC) linker is an amine-to-sulfhdryl 
crosslinker that comprises of NHS-ester and maleimide 
reactive groups located at opposite ends of a cyclohexan-
stabilized spacer arm. The NHS esters react with the 
primary amines at pH 7-9 to form suitable stable amide 
bonds. Maleimide reacts with sulhydryl groups at a pH 
of  6.5-7.5 to form stable thioether bonds. The maleimide 
group of SMCC is stable up to pH 7.5 because of the 
presence of cyclohexane bridge in the spacer arm 59,60. 
ADC production process utilizing the SMCC linker is 
characterized by steps which involve controlling the 
antibody modification (preparing the antibody for the 
conjugation reaction) and conjugation reaction 
(introduction of drug moiety) employed to achieve the 
desired level of drug loading. The molar ratio of drug to 
antibody can be adjusted by changing the reaction 
stoichiometry to deliver the desired level of potency to 
the target tissue 61. Additional steps such as removal of 
process related contamination, concentration of the 
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active pharmaceutical ingredient (API) and stabilization 
of the resulting bulk drug substance (BDS) are also 
critical steps in the manufacturing process. 
 
Figure 4: ADC Prepartion Process using non-
cleavable Succinimidyl-4-(N-maleimidomethyl) 
cyclohexan-1-1carboxylate (SMCC) linker. 
REGULATORY ASPECTS 
In order to develop and characterize the ADC certain 
analytical methods must be implemented in order  to 
verify and identify the type of MAb and cytotoxic drug 
to be used in its manufacture 62. These analytical 
techniques are used for the characterization of the ADC 
and may include protein mass spectrometry (PMS) and 
capillary electrophoresis (CE). A wide range of 
analytical tools can be effectively employed to determine 
the molecular weight of the ADC including peptide 
mapping and sequencing. The structure and linkage of 
the linker-drug combination can further be determined 
and analyzed using multi-NMR 63 and FTIR 
spectroscopic techniques 64. X-Ray crystallography can 
further be used to assess and examine the peptide or 
antibody structure and the drug to antibody ratio (DAR) 
can be suitably evaluated using UV methods 65. 
Subsequently, the application of size-exclusion 
chromatography (SEC) techniques can be used to 
determine fragmentation pattern and aggregate patterns 
during the synthesis of the ADC 66. Furthermore, the 
antigen binding and biological activity of the MAbs must 
also be assessed against ELISA, in vitro cell-based 
assays and in vivo studies 67. A critical factor which 
needs attention is to develop robust analytical methods to 
determine the level of free cytotoxic drug 68. In addition, 
chemical impurities obtained during the synthesis which 
include the impurity profile from host cell proteins must 
also be identified and characterized 69. The manufactured 
ADC must be evaluated as a new molecular entity and 
not as a separate product (antibody-linker-drug). This is 
to elucidate a structure/function relationship towards: the 
pharmacokinetics profile and low immunogenicity; the 
cytotoxic drug must demonstrate potent anti-tumour 
activity; linker has to be stable so as to enable the 
delivery of the ADC to target antigen; MAb must have 
high affinity and selectivity towards the cellular targets. 
The tumour-associated antigen expression ratio must be 
significantly high in tumours in comparison to normal 
tissue and must allow the ADC-antigen complex to be 
internalized 70.
 
Table 3: Merits & De-merits of ADC therapy 
Merits of ADC Therapy De-merits of ADC Therapy 
Selective delivery of cytotoxic drugs to 
tumour cells 
Molecular targets having similar expression may also get exposed to 
the dug leading to toxicity 
Specific binding to target antigen Requires screening of antigen of interest 
Large therapeutic index Premature release of cytotoxic drug may lead to lethal effects 
Stability of conjugate ensures extended and 
prolonged circulation half life 
Sufficient concentration may not be achieved at target site 
Reduction of adverse effects Heterogeneous antigen expression can hamper the desired results 
 (Source: Beverly A.Teicher; Ravi V.J. Chari; Clin Cancer Res; 2011; 17(20); 6389–97.) 
PRESENT AND FUTURE OF ADC’S 
Currently, there are 2 ADCs available for patients in the 
United States. However, with more than about 30 
additional molecules under clinical trials (Table 2), it is 
very likely that number of approved ADCs will enhance 
substantially in the coming decade. Moreover, this class 
of drugs provides a new opportunity to re-examine the 
future and potentially safe cytotoxic therapy. The 
combination of improved and enhanced potency with 
better tolerability profile offers the ray of hope for curing 
more life threatening cancers and, for those cancers that 
cannot be totally eradicated, ensuring an extended 
therapy and an improved quality of life for these patients. 
A century after Paul Ehrlich, his challenge has been 
taken up by a new generation of scientists who are 
working deligently to improve the specificity and activity 
of cancer chemotherapy. Although ADCs have just 
recently come up in the scenario, the evolution of the 
field is rapidly accelerating and the impact on cancer 
care is likely to be great in the years to come.
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